Alamar Biosciences partnered with the Alzheimer’s Disease Data Initiative and Gates Ventures to create a comprehensive plasma proteome atlas for Alzheimer’s and related dementias. The collaboration will combine proteomic data from multiple countries and integrate clinical outcomes to accelerate biomarker discovery, sharing results via the Global Neurodegeneration Proteomics Consortium to catalyze therapeutic development.